Hair loss treatments have remained largely unchanged for years. Men with androgenetic alopecia (male pattern baldness) typically rely on two FDA-approved medications—finasteride and topical minoxidil—while women have even fewer effective options. Hair transplantation has become increasingly refined, but surgery is only one part of a comprehensive treatment plan.
Now, a new investigational drug called VDPHL01 has generated tremendous excitement throughout the hair restoration community. Some have even labeled it the biggest pharmaceutical breakthrough in decades.
But does the science support the hype?
Let's take an objective look at what VDPHL01 is, how it works, how it differs from existing treatments, and whether it truly has the potential to change the future of hair loss treatment.
What Is VDPHL01?
VDPHL01 is an investigational extended-release oral minoxidil being developed by Veradermics. Unlike standard oral minoxidil—which was originally developed as a blood pressure medication—VDPHL01 was specifically engineered for treating pattern hair loss.
The company is currently conducting large Phase 3 clinical trials in both men and women, making it one of the most advanced investigational hair loss drugs currently in development.
This distinction is important.
Although many dermatologists and hair restoration physicians already prescribe low-dose oral minoxidil off-label, there has never been an FDA-approved oral medication designed specifically for androgenetic alopecia.
VDPHL01 aims to change that.
How Does Minoxidil Actually Work?
To understand why VDPHL01 is exciting, it helps to understand minoxidil itself.
Minoxidil is believed to work by:
- Increasing blood flow around hair follicles
- Opening potassium channels within follicle cells
- Extending the anagen (growth) phase
- Increasing follicle size
- Producing thicker terminal hairs
Unlike finasteride or dutasteride, minoxidil does not block DHT.
Instead, it stimulates follicles to produce stronger, thicker hairs regardless of hormone levels.
That makes it useful for both men and women.
So What Makes VDPHL01 Different?
This is where things become interesting.
Standard oral minoxidil works well—but because it enters the bloodstream relatively quickly, it can occasionally produce unwanted cardiovascular side effects such as:
- Lower blood pressure
- Elevated heart rate
- Swelling (fluid retention)
- Lightheadedness
These side effects are uncommon at the low doses used for hair loss but remain one reason oral minoxidil has never received FDA approval specifically for androgenetic alopecia.
VDPHL01 uses an extended-release formulation.
Instead of releasing the medication all at once, it gradually releases minoxidil over time.
The goal is to:
- Produce steadier blood levels
- Reduce peak drug concentrations
- Improve cardiovascular tolerability
- Maintain strong stimulation of hair follicles
In simple terms:
Same active medication. Smarter delivery system.
Is It Really Better Than Oral Minoxidil?
Potentially.
The biggest question isn't whether minoxidil works—we already know it does.
The question is whether an optimized formulation can produce:
- Better hair growth
- Fewer side effects
- Easier dosing
- FDA approval
If VDPHL01 accomplishes those goals, it would represent a significant advancement over compounded oral minoxidil currently prescribed off-label.
What Have Clinical Trials Shown?
The most encouraging news came from Veradermics' Phase 2/3 Study 302.
After six months of treatment:
- Patients receiving VDPHL01 experienced average increases of approximately 30–33 non-vellus hairs per square centimeter, compared with about 7 hairs/cm² in the placebo group.
- Statistically significant hair growth was observed as early as two months.
- Patients also reported noticeable cosmetic improvement.
- Reported adverse event rates were similar to placebo, and the company reported no treatment-related serious cardiac adverse events in this study.
Those are impressive results.
However, it's important to remember that these are topline trial results. Additional Phase 3 data and regulatory review are still needed before any conclusions about long-term safety and effectiveness can be made.
Is This a Cure for Baldness?
No.
This is perhaps the biggest misconception circulating online.
VDPHL01 is not:
- Hair cloning
- Follicle regeneration
- Gene therapy
- A permanent cure
It is still a medication.
Like finasteride or topical minoxidil, treatment would likely need to continue to maintain results if approved.
Stopping therapy would likely allow genetically susceptible follicles to resume miniaturization over time.
Who Could Benefit Most?
If approved, VDPHL01 could become especially attractive for:
Men with early thinning
Those who are beginning to lose density but want stronger medical therapy.
Women with pattern hair loss
Women have relatively few FDA-approved options.
Veradermics is also conducting clinical trials specifically for female pattern hair loss, potentially addressing a major unmet need.
Patients who dislike topical treatments
Many people simply dislike applying topical minoxidil every day.
A once-daily pill may significantly improve convenience and adherence.
Hair transplant patients
Medical therapy remains one of the most important ways to protect native hair after surgery.
If VDPHL01 proves effective and safe, it could become an excellent companion treatment for maintaining long-term results.
How Does It Compare to Finasteride?
This is where expectations should remain realistic.
Finasteride and dutasteride reduce DHT, the hormone primarily responsible for androgenetic alopecia. They slow or halt follicle miniaturization.
VDPHL01 works through a different mechanism by stimulating hair growth rather than lowering DHT.
For many patients, these approaches may be complementary rather than competitive. In clinical practice today, physicians often combine DHT-blocking medications with minoxidil-based therapies to address hair loss from multiple angles. Whether VDPHL01 will ultimately be used in the same way will depend on future research and regulatory approval.
What About Safety?
This remains one of the biggest unanswered questions.
Although early studies appear encouraging, Phase 3 trials are specifically designed to evaluate safety across much larger patient populations.
Researchers will continue assessing:
- Blood pressure effects
- Heart rate
- Swelling
- Long-term tolerability
- Rare adverse events
Until the full Phase 3 program is complete and reviewed by regulators, it's too early to conclude that VDPHL01 is safer than existing oral minoxidil.
Could This Become FDA Approved?
Possibly.
Veradermics is currently conducting multiple pivotal Phase 3 studies, including trials in men and women. One large male Phase 3 study completed enrollment in early 2026, while additional studies remain underway.
If these trials continue to produce positive results and satisfy regulatory requirements, VDPHL01 could become the first oral medication specifically approved for pattern hair loss in decades.
That alone would represent a major milestone.
Is This the Biggest Hair Loss Breakthrough?
It depends on how you define "breakthrough."
Why it could be
- First purpose-built oral minoxidil formulation
- Positive late-stage clinical data
- Potentially improved safety profile
- Convenient once-daily dosing
- Development for both men and women
- Could expand access to an effective oral treatment if approved
Why we should remain cautious
- Long-term data are still being collected.
- Full Phase 3 results have not yet been completed across all studies.
- Regulatory approval has not yet been granted.
- Real-world performance sometimes differs from clinical trials.
In other words, VDPHL01 is extremely promising—but it has not yet crossed the finish line.
The Bottom Line
VDPHL01 represents one of the most exciting developments in hair restoration today. Rather than introducing a completely new drug, Veradermics has taken a medication with a well-established ability to stimulate hair growth and redesigned its delivery to potentially maximize benefits while minimizing unwanted cardiovascular effects.
If ongoing Phase 3 trials continue to confirm its efficacy and safety, VDPHL01 could become an important new option for both men and women with pattern hair loss and may set a new standard for oral medical therapy.
At the same time, it's important to avoid the hype that often surrounds investigational treatments. VDPHL01 is not a cure for baldness, nor is it likely to replace every existing therapy. Hair loss is a complex, progressive condition, and the most effective treatment plans are typically individualized—often combining medications, lifestyle considerations, and, when appropriate, hair transplantation.
If you're trying to separate marketing from science, one of the best resources is to learn directly from real patients. Thousands of men and women openly document their treatment journeys—including medical therapies, hair transplant results, successes, setbacks, and long-term follow-up—on the Hair Restoration Network.
To stay informed about VDPHL01, PP405, HMI-115, verteporfin research, the latest clinical trials, and evidence-based advances in hair restoration, be sure to subscribe to the Hair Transplant Network newsletter. You'll receive updates on emerging treatments, expert commentary, and educational content designed to help you make informed decisions rather than relying on internet hype.
The future of hair restoration has never been more exciting—but informed patients consistently make the best decisions. The Hair Restoration Network community remains one of the best places to follow new developments, compare real-world experiences, and learn which treatments are truly delivering results.